AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMAG
  • CUSIP: 00163U10
  • Web: www.amagpharma.com
Capitalization:
  • Market Cap: $634.31 million
  • Outstanding Shares: 35,045,000
Average Prices:
  • 50 Day Moving Avg: $21.56
  • 200 Day Moving Avg: $25.91
  • 52 Week Range: $17.90 - $36.83
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 7.64
  • P/E Growth: -0.320
Sales & Book Value:
  • Annual Revenue: $562.26 million
  • Price / Sales: 1.13
  • Book Value: $26.83 per share
  • Price / Book: 0.67
Profitability:
  • EBIDTA: $246.86 million
  • Net Margins: 3.12%
  • Return on Equity: 11.10%
  • Return on Assets: 4.13%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.12%
Misc:
  • Average Volume: 1.19 million shs.
  • Beta: 1.09
  • Short Ratio: 7.22
 

Frequently Asked Questions for AMAG Pharmaceuticals (NASDAQ:AMAG)

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) released its earnings results on Tuesday, May, 2nd. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of $0.09 by $1.15. The business had revenue of $139.47 million for the quarter, compared to the consensus estimate of $150.32 million. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The firm's revenue for the quarter was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.22) earnings per share. View AMAG Pharmaceuticals' Earnings History.

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2017?

11 equities research analysts have issued 1-year target prices for AMAG Pharmaceuticals' shares. Their forecasts range from $23.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $30.50 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "When no news may be good news. With the sNDA for the Makena auto-injector filed in April, we believe the best that investors might hope for is no commentary from AMAG until FDA approval. Any deviation from what we view as a tight timeline (4Q17 approval and Makena Orphan exclusivity expiration February 3, 2018), could raise concerns about the franchise’s durability, in our opinion. Needle-moving ability of new maternal health assets remains to be determined. We previously published our thoughts on bremelanotide and Intrarosa, valuing the former at ~$7 per share and the latter at ~$1 per share. AMAG anticipates launching Intrarosa in the mid-2017 supported by a new 150- person sales force. Daily dosing will offset any advantage absence of a black box warning on the label might confer, in our opinion." (5/2/2017)
  • 2. Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)
  • 3. Guggenheim analysts commented, "Despite near-term setbacks, we continue to believe patience will be rewarded for AMAG investors with a longer-term horizon. However we are lowering our price target to $28 from $42. Our PT reduction is driven by lowered expectations for Makena life cycle extension. We believe Makena Sub-Q will face a challenging reimbursement environment, if approved, given the pain and Cmax PK data released this morning and expect generics to capture the majority of the market from '18+. Longer term stock price appreciation could be driven by Feraheme label expansion, CBR durability, Business Development, and Rekynda keep us positive." (2/2/2017)
  • 4. According to Zacks Investment Research, "We are concerned about AMAG’s dependence on sales of Makena, which primarily drives the company’s top line. We are also concerned about the company’s iron replacement therapy, Feraheme, which faces patent challenge in the U.S. In addition, inclusion of a boxed warning in Feraheme’s label is concerning. Moreover, termination of the marketing agreement with Takeda is a major setback for the company. Stiff competition and generic threats remain a woe as well. Estimates are stable ahead the company’s Q4 release. The company has recorded an average negative earnings surprise over the four trailing quarters. However, AMAG’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/9/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.00%), Palo Alto Investors LLC (9.54%), Vanguard Group Inc. (0.00%), State Street Corp (7.20%), CAMBER CAPITAL MANAGEMENT LLC (7.13%) and LSV Asset Management (4.91%). Company insiders that own AMAG Pharmaceuticals stock include Frank E Thomas, John A Fallon, Julie Krop, Scott A Holmes and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Ameriprise Financial Inc., Janus Capital Management LLC, Bank of America Corp DE, Schwab Charles Investment Management Inc., Falcon Point Capital LLC, Systematic Financial Management LP and Alliancebernstein L.P.. View Insider Buying and Selling for AMAG Pharmaceuticals.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, State Street Corp, Dimensional Fund Advisors LP, Perceptive Advisors LLC, LSV Asset Management, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AMAG Pharmaceuticals stock cost?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $18.10.

Analyst Ratings

Consensus Ratings for AMAG Pharmaceuticals (NASDAQ:AMAG) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $30.50 (68.51% upside)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Barclays PLCReiterated RatingHold$25.00N/AView Rating Details
5/11/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/3/2017Jefferies Group LLCReiterated RatingBuy$40.00 -> $34.00HighView Rating Details
5/2/2017Cantor FitzgeraldReiterated RatingHold$23.00HighView Rating Details
2/3/2017Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017JPMorgan Chase & Co.Set Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/10/2017Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market Perform$39.00 -> $25.00N/AView Rating Details
1/9/2017Raymond James Financial, Inc.Reiterated RatingMarket Perform -> UnderperformN/AView Rating Details
5/9/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $35.00N/AView Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00N/AView Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings History by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
2017 EPS Consensus Estimate: $0.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.05)($1.05)($1.05)
Q2 20171$0.58$0.58$0.58
Q3 20171$0.43$0.43$0.43
Q4 20171$0.57$0.57$0.57
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Ownership Percentage: 2.30%
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Julie KropSVPSell1,891$24.45$46,234.95View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.40View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AMAG Pharmaceuticals (NASDAQ:AMAG)
Latest Headlines for AMAG Pharmaceuticals (NASDAQ:AMAG)
Source:
DateHeadline
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 22 at 10:29 AM
nasdaq.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs - Nasdaq
www.nasdaq.com - May 16 at 3:32 PM
finance.yahoo.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
finance.yahoo.com - May 16 at 3:32 PM
finance.yahoo.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
finance.yahoo.com - May 16 at 3:32 PM
reuters.com logoBRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals
www.reuters.com - May 15 at 3:27 PM
globenewswire.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy - GlobeNewswire (press release)
globenewswire.com - May 15 at 3:27 PM
finance.yahoo.com logoBear of the Day: AMAG Pharmaceuticals (AMAG)
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoBear of the Day: AMAG Pharmaceuticals (AMAG)
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAlpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAlpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - May 15 at 3:27 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 13 at 3:22 PM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. -- Moody's upgrades AMAG's sr. notes to Ba3; affirms B2 CFR
finance.yahoo.com - May 12 at 4:02 PM
nasdaq.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New ... - Nasdaq
www.nasdaq.com - May 11 at 1:42 AM
globenewswire.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New York - GlobeNewswire (press release)
globenewswire.com - May 10 at 3:38 PM
zacks.com logoWhat Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?
www.zacks.com - May 10 at 9:24 AM
finance.yahoo.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New York
finance.yahoo.com - May 10 at 9:24 AM
americanbankingnews.com logoTheStreet Lowers AMAG Pharmaceuticals, Inc. (AMAG) to D+
www.americanbankingnews.com - May 9 at 3:50 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Earns Hold Rating from Barclays PLC
www.americanbankingnews.com - May 7 at 9:26 AM
streetinsider.com logoAMAG Pharma (AMAG) Prices Offering of $300M 3.25% Convertible Senior Notes Due 2022
www.streetinsider.com - May 6 at 1:32 AM
reuters.com logoBRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln
www.reuters.com - May 6 at 1:32 AM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 6 at 1:32 AM
finance.yahoo.com logoETFs with exposure to AMAG Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 8:30 PM
streetinsider.com logoForm FWP AMAG PHARMACEUTICALS Filed by: AMAG PHARMACEUTICALS INC. - StreetInsider.com
www.streetinsider.com - May 5 at 3:30 PM
reuters.com logoBRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln - Reuters
www.reuters.com - May 5 at 3:30 PM
americanbankingnews.com logo$0.09 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - May 4 at 10:50 PM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. -- Moody's: AMAG's proposed refinancing credit positive
finance.yahoo.com - May 4 at 8:31 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 3 at 9:52 PM
nasdaq.com logoAMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - May 3 at 8:34 PM
finance.yahoo.com logoAMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 2022 - Yahoo Finance
finance.yahoo.com - May 3 at 8:34 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Likely to Affect AMAG Pharmaceuticals (AMAG) Share Price
www.americanbankingnews.com - May 3 at 7:18 PM
finance.yahoo.com logoAMAG Pharmaceuticals reports 1Q loss - Yahoo Finance
finance.yahoo.com - May 3 at 3:33 PM
finance.yahoo.com logoAMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y
finance.yahoo.com - May 3 at 3:33 PM
seekingalpha.com logoAMAG Pharmaceuticals, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 8:41 AM
finance.yahoo.com logoAMAG Pharmaceuticals reports 1Q loss
finance.yahoo.com - May 3 at 8:41 AM
finance.yahoo.com logoEdited Transcript of AMAG earnings conference call or presentation 2-May-17 12:00pm GMT
finance.yahoo.com - May 3 at 8:41 AM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) SVP Sells $46,234.95 in Stock
www.americanbankingnews.com - May 2 at 10:22 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Hold" Rating for AMAG Pharmaceuticals, Inc. (AMAG)
www.americanbankingnews.com - May 2 at 5:46 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Posts Earnings Results, Misses Expectations By $2.69 EPS
www.americanbankingnews.com - May 2 at 3:32 PM
reuters.com logoBRIEF-AMAG Pharmaceuticals posts Q1 loss per share $1.06 - Reuters
www.reuters.com - May 2 at 3:32 PM
finance.yahoo.com logoAMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - May 2 at 7:30 AM
finance.yahoo.com logoAMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
finance.yahoo.com - May 2 at 7:30 AM
finance.yahoo.com logoInvestor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 7:30 AM
finance.yahoo.com logoAMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 2 at 7:30 AM
americanbankingnews.com logoSomewhat Negative Press Coverage Very Likely to Impact AMAG Pharmaceuticals (AMAG) Stock Price
www.americanbankingnews.com - April 30 at 11:39 AM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:02 AM
bizjournals.com logoJohn Tucker appointed as Chief Executive Officer of scPharmaceuticals
www.bizjournals.com - April 27 at 1:43 AM
globenewswire.com logoAMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance - GlobeNewswire (press release)
globenewswire.com - April 26 at 3:41 PM
nasdaq.com logoAMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference - Nasdaq
www.nasdaq.com - April 26 at 3:41 PM

Social

Chart

AMAG Pharmaceuticals (AMAG) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff